Mild glucose intolerance during pregnancy may herald cardiovascular disease, according to the results of a retrospective, population-based cohort study in 435,700 Canadian women.
Mild glucose intolerance during pregnancy may herald cardiovascular disease, according to the results of a retrospective, population-based cohort study in 435,700 Canadian women.
Compared with those who were not given the test because they had a normal result on a glucose challenge test, women in the study who did not have diabetes but who were administered an oral glucose tolerance test because of an abnormal result on a 50-g glucose challenge test were almost 20% more likely within the 12.3-year median follow-up period to be admitted to a hospital for acute myocardial infarction, coronary bypass, coronary angiogram, stroke, or carotid endarterectomy (adjusted hazard ratio [HR], 1.19; 95% confidence interval [CI], 1.02-1.39; P=.03).
The study included women in Ontario, Canada, between the ages of 20 and 49 years who delivered a live fetus between April 1994 and March 1998 and did not have pregestational diabetes. Approximately 350,000 of the women did not receive an oral glucose tolerance test because they had a normal result on a challenge test. About 72,000 women received an antepartum oral glucose tolerance test because of an abnormal result on a glucose challenge test, and almost 14,000 women were diagnosed with gestational diabetes. All of the women were followed for a mean of 12.3 years.
Retnakaran R, Shah BR. Mild glucose intolerance in pregnancy and risk of cardiovascular disease: a population-based cohort study. CMAJ. 2009;181(6-7):371-376.
SKYLIGHT trials confirm safety and efficacy of fezolinetant against sleep disturbances
September 13th 2024At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.
Read More
Study shows hormone therapy offers lasting benefits for women over 65
September 12th 2024A new study presented at the 2024 Annual Meeting of The Menopause Society shows hormone therapy remains beneficial for women over 65, helping manage menopause symptoms like hot flashes and improving quality of life.
Read More